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Clinical outcomes of TS-1 chemotherapy for advanced 
and recurrent gastric cancer
Sung Ryol Lee, Hyung Ook Kim, Chang Hak Yoo
Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Purpose: Titanium silicate (TS)-1 chemotherapy has been widely used against gastric cancer in Japan. The aim of the present 
study was to assess the efficacy and hematological safety of TS-1 as treatment for advanced and recurrent gastric cancer. 
Methods: From September 2006 to February 2011, 51 advanced or recurrent gastric cancers were treated with TS-1. One 
course of treatment consisted of 40, 50, or 60 mg/m
2 of TS-1 twice a day for 28 days, followed by withdrawal for two weeks. 
The primary end point was progression-free survival (PFS), and the secondary end point was overall survival (OS). Results: 
The disease control rate was 39.2% (complete response, 0/51; partial response, 6/51; stable disease, 14/51; progressive disease, 
23/51; not evaluable, 8/51). The median PFS was 4.0 months (95% confidence interval [CI], 2.2 to 5.7); the median PFS of the 
advanced group was 6.0 months (95% CI, 2.8 to 9.1), and the median PFS of the recurrent group was 3.0 months (95% CI, 1.8 
to 4.1). The median OS was 11.0 months (95% CI, 6.3 to 15.6); the median OS of the advanced group was 10.0 months (95% CI, 
4.9 to 15.0), and the median OS of the recurrent group was 14.0 months (95% CI, 4.1 to 23.8). Grade 3 or 4 hematological tox-
icity occurred in three patients (5.9%), anemia occurred in two patients (3.9%), and thrombocytopenia occurred in one patient 
(2%). Conclusion: TS-1 chemotherapy was safe and effective, with relatively long PFS and OS in patients with advanced and 
recurrent gastric cancers.
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INTRODUCTION
In Korea, gastric cancer is the most common form of 
cancer (data from the Ministry of Health & Welfare, 2008). 
Early detection and curative surgery can improve survival 
of loco-regional gastric cancer [1], but the survival rates of 
far advanced and recurrent gastric cancers remain very 
low. Various approaches have been tried for far advanced 
and recurrent gastric cancers, including 5-fluorouracil 
(5-FU). Two pivotal phase II studies performed in Japan 
that evaluated the use of titanium silicate (TS)-1 in ad-
vanced gastric cancer showed response rates of 44% and 
49%, times to progression of 135 and 158 days, and overall 
survivals (OS) of 207 and 250 days, respectively [2,3]. TS-1 
is based on a biochemical modulation of 5-FU and contains 
tegafur, gimeracil and oteracil potassium in a molar ratio 
of 1:0.4:1 [4]. As a result of its structure, TS-1 has an in-
creased anti-tumor effect and fewer adverse reactions Sung Ryol Lee, et al.
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Characteristic No. of patients
Age (yr), median (range) 62 (51-71)
Sex
 Male 
  Female 
32
19
Performance status (ECOG)
  0
  1
  2
  3
 3
31
17
 0
Histologic type
 Intestinal type 
  Diffuse type 
19
32
History of gastrectomy
 ＋
  －
30
21
Metastatic site
      Peritoneum 
  Organ
 Liver 
Bone 
Others 
29
10 
  5
 7
ECOG, Eastern Clinical Oncology Group.
Table 1. Patient demographics and characteristics
compared to those of 5-FU. In the present study, we inves-
tigated the outcome, adverse reactions, and characteristics 
of long-term survivors of far advanced and recurrent gas-
tric cancers who had received TS-1.
METHODS 
The present study was based on a prospectively de-
signed database of gastric cancer patients at the Depart-
ment of Surgery, Kangbuk Samsung Hospital. The ethics 
committee at our institution approved the protocol. 
Between September 2006 and February 2011, 51 patients 
with either far advanced (locally advanced unresectable or 
metastatic disease) or recurrent (loco-regional, peritoneal, 
hematogenous metastasis after curative resection) gastric 
cancer were treated with TS-1. Analyses were performed 
according to the intention to treat principle. The initial 
dosage of TS-1 was calculated based on body surface area 
(BSA), and the patients received one of the following oral 
dosages twice daily after meals: 40 mg for patients with 
BSA ＜1.25 m
2, 50 mg for BSA ≥1.25 m
2 and ＜1.50 m
2, and 
60 mg for BSA ≥1.50 m
2. One cycle of therapy involved the 
administration of TS-1 as a single agent for 28 consecutive 
days, followed by 14 days without treatment. This sched-
ule was repeated every six weeks until the occurrence of 
disease progression, unacceptable toxicity, or patient 
refusal.
 Measurement of efficacy was conducted every three 
months using abdominal pelvic computed tomography 
(CT) or positron emission tomography-CT. Laboratory 
tests were also conducted every three months. The re-
sponses of the lesions were evaluated using the Response 
Evaluation Criteria In Solid Tumors. Progression-free sur-
vival (PFS) was defined as the period from the date of the 
first course of chemotherapy to the date of disease pro-
gression or death. OS was defined as the period from the 
date of the first course of chemotherapy to the date of 
death from any cause. If neither event had occurred at the 
time of the last record, the patient was censored at that 
time. 
During all of the treatment courses, toxicity was graded 
according to the National Cancer Institute Common Cri-
teria. All of the data are presented as median values with 
ranges. The significances of the differences between the re-
sults were tested using the Chi-square test, Fisher’s exact 
test, or Mann-Whitney test. P-values ＜  0.05 were consid-
ered statistically significant. PFS and OS were analyzed 
using the Kaplan-Meier method, and statistically sig-
nificant differences in survival were identified using the 
log rank test. Statistical analysis was performed with a 
statistical analysis package SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Patient demographics and characteristics
The baseline characteristics of the 51 patients are listed 
in Table 1. Thirty-two male and 19 female patients were 
evaluated in this study, and the median age was 62 years 
(range, 51 to 71). Most patients had a pretreatment per-
formance status (PS) of 0 to 1, and 30 patients (58.8%) had 
a history of gastrectomy (23 curative resection and 7 pallia-
tive resection) before chemotherapy was initiated. On his-Efficacy of TS-1 in gastric cancer
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Classification CR PR SD PD NE DCR, n (%) P-value TDCR, n (%)
Metastatic site 0.133
  Peritoneum 0 3 10 12 4 13/29 (44.8)
  Organ
20/51 (39.2%)
   L i v e r 0 2  1 70
  7/22 (31.8)  B o n e 0 0  0 23
 O t h e r s 0 1  3 21
Disease status
  Far advanced  0 3 11 10 4
                     
14/28 (50.0) 0.095
  Recurrent 0 3  3 13 4  6/23 (26.1)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; DCR, disease control rate; TDCR, 
total disease control rate.
Table 2. Responses to treatment (n = 51)
Fig. 1. Overall survival curve for all patients. The median survival 
time was 11.0 months with 1-, 2-, and 3-year survival rates of 49.0%, 
24.8%, and 19.8%, respectively.
tology, 19 patients (37.2%) had intestinal-type and 32 pa-
tients (62.8%) had diffuse-type adenocarcinoma. Major 
sites of metastases were the peritoneum in 29 patients 
(56.8%), liver in ten (19.6%), bone in five (9.8%), and other 
locations in seven (13.8%).
Response and survival
Disease control rates (DCR) are listed in Table 2. Of the 
51 patients, six (11.8%) achieved a partial response (PR) 
and 14 (27.4%) achieved stable disease (SD), with a DCR of 
39.2% (20/51) on the intention to treat analysis. The DCR 
was 46.5% (20/43) in patients with evaluable lesions. The 
DCR according to the site of metastasis was somewhat 
higher for peritoneal metastasis (44.8%) than it was at oth-
er sites (31.8%), which included liver, bone, ovary, and oth-
er sites. However, the DCR was not statistically different 
according to metastasis site (P = 0.133). Evaluation of the 
DCR by disease status revealed a value of 50.0% for the far 
advanced group and 26.1% for the recurrent group. The 
far advanced group tended to have a higher incidence of 
disease control; however, there was not a statistically sig-
nificant intergroup difference in DCR (P = 0.095). The me-
dian OS after the initiation of TS-1 administration in all 51 
patients was 11 months (95% CI, 6.4 to 15.6). The one-, 
two-, and three-year survival rates were 49.0%, 24.8%, and 
19.8%, respectively (Fig. 1). The median PFS was 4.0 
months (95% CI, 2.3 to 5.7). Patients with intestinal-type 
(35.8%) tended to have a higher two-year survival rate 
than those with diffuse-type (18.0%). There were seven pa-
tients who survived for longer than two years, and their 
characteristics are listed in Table 3. Five of the seven pa-
tients surviving longer than two years had a good PS of 0 
or 1. Of these seven patients, five (71.4%) had intestinal- 
type adenocarcinoma. Surgical resection performed in six 
(1 palliative total gastrectomy and splenectomy, 5 curative 
subtotal gastrectomy) of the seven patients before the start 
of TS-1 chemotherapy, and the remaining patient did not 
undergo gastrectomy. All of seven patients have not any 
postoperative complication. The metastasis sites in these 
seven patients included the peritoneum in two and a spe-
cific organ in five. Three of the seven patients were alive 
with no apparent tumor progression at two years after 
TS-1 chemotherapy. Sung Ryol Lee, et al.
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Age (yr) Sex PS HIS Site of metastasis Gastrectomy Response Cycle Survival (mo) Present status
64 M 2 I Peritoneum － SD 12 26 Dead
60 M 2 I Peritoneum ＋ SD  6 39 Alive
78 M 0 I Port-site ＋ SD  6 39 Alive
70 F 1 I Liver ＋ SD  9 27 Dead
62 F 0 I Liver ＋ PR  6 41 Alive
62 M 1 D Lung ＋ SD 12 24 Alive
51 F 1 D Ovary ＋ SD 14 24 Alive
PS, performance status; HIS, histology; I, intestinal type; D, diffuse type; SD, stable disease; PR, partial response.
Table 3. Two-year survivors treated with TS-1
Toxicity
Grade (NCI-CTC)
123 4
Grade 
3/4 (%)
Leukopenia 46   5 0 0 0.0
Neutropenia 46   5 0 0 0.0
Anemia 29 20 1 1 3.9
Thrombocytopenia 48   2 0 1 2.0
NCI-CTC, National Cancer Institute-Common Toxicity Criteria.
Table 4. Hematological adverse reactions
Adverse reactions
The adverse reactions that occurred throughout the 
treatment course are shown in Table 4. Adverse reactions 
were mostly mild; grade 3 or 4 hematological toxicities oc-
curred in 5.9% of patients, and grade 3 or 4 adverse re-
actions with anemia were seen in two patients (3.9%). Of 
the 51 patients, only one (2%) had a grade 4 adverse re-
action, which was thrombocytopenia. There were no che-
motherapy-related deaths.
DISCUSSION
In gastric cancer, early detection and curative resection 
can improve survival in patients with loco-regional gastric 
cancer [1], but far advanced or recurrent gastric cancers 
are mostly treated with chemotherapy. Low dose 5-FU and 
cisplatin treatment (FP) were frequently used in Japan in 
the 1990s due to their low toxicities and high anti-tumor 
effects [5-7]. A randomized study conducted by the 
European Organization for Research and Treatment of 
Cancer reported a median PFS of 4.1 months and a median 
OS of 7.2 months with FP [8]. However, the disadvantage 
of FP was long-term hospitalization during treatment 
[8,9]. Furthermore, in a Japanese phase III study, 5-FU 
alone was shown to provide a survival benefit almost 
equivalent to that of FP , with less toxicity and an appa-
rently better quality of life. 5-FU alone has a median PFS of 
1.9 months and a median OS of 7.1 months, and the me-
dian PFS and median OS achieved with FP were 3.9 
months and 7.3 months, respectively [9]. In the present 
study, the median PFS and OS of patients receiving TS-1 
chemotherapy were 4.0 and 11.0 months, respectively, 
which were relatively longer than those of patients treated 
with 5-FU alone or FP in the Japanese phase III trial. 
In the present study, the DCR was 39.2%, which con-
sisted of a PR rate of 11.8% and an SD rate of 27.5%, and OS 
was 11 months. Up to now, no combination chemotherapy 
using conventional agents has contributed to a prolonged 
median OS longer than ten months. When compared with 
previous studies using combination chemotherapy, such 
as FAMTX (5-FU, doxorubicin, methotrexate), FAM (5-FU, 
doxorubicin, mitomycin C), and FP, our results demon-
strated relatively low response rates and longer OS for the 
treatment of advanced gastric cancer [10-12]. A reason for 
the difference between the low response rate and rela-
tively high OS is that peritoneal metastasis was the pre-
dominant metastatic pattern in far advanced and re-
current gastric cancers. It is usually difficult to measure 
the lesions in patients with peritoneal metastasis because 
small nodules cannot be precisely measured using CT 
[13,14]. Therefore, most patients with peritoneal meta-
stasis are regarded as having SD. 
Laparoscopy is very useful for evaluating the response Efficacy of TS-1 in gastric cancer
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of peritoneal metastasis in gastric cancer to chemotherapy 
[15]. However, routine and repeated use of laparoscopy is 
impractical. If the response to chemotherapy for peri-
toneal disease were measured more precisely, the ratio of 
PR and SD would change because TS-1 has been reported 
to have the potential to prolong the survival of patients 
with peritoneal dissemination [16,17]. An experimental 
study to assess the effect of TS-1 on peritoneal dissem-
ination of gastric cancer has confirmed that a high concen-
tration of 5-FU is maintained in intra-peritoneal tumors af-
ter TS-1 administration, and that survival time is pro-
longed without any decrease in oral food intake or body 
weight [18].
The present study shows that all of the patients treated 
with TS-1 had an adverse hematological reaction. Howev-
er, severe, grade 3 and 4 adverse reactions only occurred in 
5.9% of the patients, and this frequency was consistent 
with frequencies of 4.0% and 5.9% of grade 3 or more ad-
verse reactions reported in previous studies [19,20]. The 
other adverse reactions were generally mild and tolerable, 
and dose modifications or discontinuations were rarely 
necessary.
In the present study, seven patients survived longer 
than two years. Five of those seven patients had good PS, 
and all had a single organ metastasis, either in the peri-
toneum alone or in a specific organ, such as a port site, liv-
er, ovary, or lung. They received a median of nine cycles of 
TS-1 treatment, and four of the patients received sec-
ond-line chemotherapy (doxifluridine or tegafur ＋  uracil) 
after disease progression. Long-term treatment with TS-1 
and the second-line treatment may have prolonged their 
survival. Three patients had PFS for two years and had a 
single organ metastasis, such as in a port site, the liver, or 
the lungs. Those were detected during follow-up using 
imaging studies, and local treatment, such as radio fre-
quency ablation or resection, was immediately performed. 
After local control of metastasis, they were treated with 
TS-1. 
Our previous study reported that patients with meta-
stasis from gastric cancer may not expect long-term sur-
vival with only local control of cancer in the liver due to in-
trahepatic recurrence from multiple metastatic foci that 
originated from the primary disease [21]. Several studies 
have suggested that combined therapy that includes ag-
gressive local treatment and early postoperative adjuvant 
chemotherapy for advanced gastric cancer with liver 
metastasis may allow long-term survival in selected pa-
tients [21-23]. The present study suggests that combined 
therapy with local control and TS-1 could increase PFS if 
local control of metastasis can be achieved.
Several studies have surveyed prognostic factors of ad-
vanced gastric cancer. Poor PS, liver metastases, peritoneal 
metastases, an elevated alkaline phosphatase level, multi-
ple metastatic sites, and a histological diffuse-type tumor 
have been shown to be associated with poor survival 
[24-27]. The present study also shows that patients with in-
testinal-type histology (median survival time, 14 months; 
95% CI, 6.34 to 21.65) tended to have longer survival than 
did those with diffuse-type (median survival time, 9 
months; 95% CI, 6.34 to 21.65), although the P-value was 
not statistically significant (P = 0.108). Therefore, a study 
focusing on more optimal inclusion criteria needs to be 
performed.
In conclusion, TS-1 chemotherapy was safe and effec-
tive with a relatively higher DCR and longer OS in patients 
with far advanced and recurrent gastric cancers and TS-1 
had various advantages, such as its convenient oral form 
and mild adverse reactions. However, a prospective 
randomized controlled trial with a larger number of pa-
tients needs to be performed to confirm these results.
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